Chiasma to Report Fourth Quarter and Year End 2015 Financial Results on March 14
26 févr. 2016 08h00 HE
|
Chiasma, Inc.
NEWTON, Mass., Feb. 26, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company developing Mycapssa™ (octreotide) capsules, a new investigational oral drug for...
Chiasma to Present at Upcoming Investor Conferences
25 févr. 2016 08h00 HE
|
Chiasma, Inc.
NEWTON, Mass., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company developing Mycapssa™ (octreotide) capsules, a new investigational oral drug for...
Chiasma Reviews 2015 Accomplishments and Outlines Core Objectives for 2016
08 janv. 2016 08h00 HE
|
Chiasma, Inc.
Ended 2015 with Between $148 Million and $149 Million in Cash, Cash Equivalents and Marketable Securities, Which the Company Believes is Sufficient to Fund Operations at Least Through Mid-2017 ...
Chiasma Expands Senior Management Team With Key Strategic Hires
04 janv. 2016 08h00 HE
|
Chiasma, Inc.
NEWTON, Mass., Jan. 04, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company developing Mycapssa™ (octreotide capsules), an investigational oral drug for...
Chiasma Announces Addition of James R. Tobin and John F. Thero to Board of Directors
30 nov. 2015 08h00 HE
|
Chiasma, Inc.
NEWTON, Mass., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company developing Mycapssa™ (octreotide capsules), an investigational oral drug for...
Chiasma Reports Third Quarter 2015 Financial Results and Recent Business Highlights
12 nov. 2015 16h01 HE
|
Chiasma, Inc.
– Builds out infrastructure in advance of April 15, 2016 PDUFA target date –
– EMA accepts Phase 3 trial design –
– Conference call scheduled for 5 p.m. ET today...
Chiasma to Present at Upcoming Investor Conferences
11 nov. 2015 08h00 HE
|
Chiasma, Inc.
NEWTON, Mass., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company developing Mycapssa™ (octreotide capsules), an investigational oral drug for...
Chiasma to Report Third Quarter 2015 Financial Results on November 12
29 oct. 2015 08h00 HE
|
Chiasma, Inc.
NEWTON, Mass., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company developing Mycapssa™ (octreotide capsules), an investigational oral drug for...